Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
UPI's Cash to Debt is ranked higher than
86% of the 377 Companies
in the Global Medical Devices industry.

( Industry Median: 6.28 vs. UPI: No Debt )
UPI' s 10-Year Cash to Debt Range
Min: 1.25   Max: No Debt
Current: No Debt

Equity to Asset 0.80
UPI's Equity to Asset is ranked higher than
83% of the 358 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. UPI: 0.80 )
UPI' s 10-Year Equity to Asset Range
Min: 0.39   Max: 0.91
Current: 0.8

0.39
0.91
F-Score: 3
Z-Score: 9.66
M-Score: -3.45
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -14.72
UPI's Operating margin (%) is ranked higher than
52% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 6.25 vs. UPI: -14.72 )
UPI' s 10-Year Operating margin (%) Range
Min: -87.55   Max: 15.27
Current: -14.72

-87.55
15.27
Net-margin (%) -14.74
UPI's Net-margin (%) is ranked higher than
52% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 4.82 vs. UPI: -14.74 )
UPI' s 10-Year Net-margin (%) Range
Min: -73.95   Max: 9.41
Current: -14.74

-73.95
9.41
ROE (%) -19.81
UPI's ROE (%) is ranked higher than
52% of the 365 Companies
in the Global Medical Devices industry.

( Industry Median: 5.79 vs. UPI: -19.81 )
UPI' s 10-Year ROE (%) Range
Min: -133.34   Max: 23.56
Current: -19.81

-133.34
23.56
ROA (%) -16.49
UPI's ROA (%) is ranked higher than
53% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: 3.09 vs. UPI: -16.49 )
UPI' s 10-Year ROA (%) Range
Min: -70.97   Max: 14.22
Current: -16.49

-70.97
14.22
ROC (Joel Greenblatt) (%) -151.21
UPI's ROC (Joel Greenblatt) (%) is ranked lower than
51% of the 379 Companies
in the Global Medical Devices industry.

( Industry Median: 12.55 vs. UPI: -151.21 )
UPI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -494.76   Max: 48.21
Current: -151.21

-494.76
48.21
Revenue Growth (%) 11.00
UPI's Revenue Growth (%) is ranked higher than
84% of the 278 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. UPI: 11.00 )
UPI' s 10-Year Revenue Growth (%) Range
Min: -23.7   Max: 11
Current: 11

-23.7
11
EBITDA Growth (%) -8.40
UPI's EBITDA Growth (%) is ranked higher than
69% of the 249 Companies
in the Global Medical Devices industry.

( Industry Median: -3.70 vs. UPI: -8.40 )
UPI' s 10-Year EBITDA Growth (%) Range
Min: -38.3   Max: 214.1
Current: -8.4

-38.3
214.1
EPS Growth (%) -8.70
UPI's EPS Growth (%) is ranked higher than
66% of the 233 Companies
in the Global Medical Devices industry.

( Industry Median: -2.80 vs. UPI: -8.70 )
UPI' s 10-Year EPS Growth (%) Range
Min: -29   Max: 45.5
Current: -8.7

-29
45.5
» UPI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

UPI Guru Trades in Q1 2013

Jim Simons 28,600 sh (New)
» More
Q2 2013

UPI Guru Trades in Q2 2013

Jim Simons 47,300 sh (+65.38%)
» More
Q3 2013

UPI Guru Trades in Q3 2013

Jim Simons 73,000 sh (+54.33%)
» More
Q4 2013

UPI Guru Trades in Q4 2013

Jim Simons 78,100 sh (+6.99%)
» More
» Details

Insider Trades

Latest Guru Trades with UPI



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.10
UPI's P/B is ranked lower than
63% of the 355 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. UPI: 5.10 )
UPI' s 10-Year P/B Range
Min: 0.44   Max: 11.07
Current: 5.1

0.44
11.07
P/S 2.90
UPI's P/S is ranked higher than
52% of the 372 Companies
in the Global Medical Devices industry.

( Industry Median: 2.74 vs. UPI: 2.90 )
UPI' s 10-Year P/S Range
Min: 0.38   Max: 11.49
Current: 2.9

0.38
11.49
EV-to-EBIT 10.60
UPI's EV-to-EBIT is ranked higher than
89% of the 293 Companies
in the Global Medical Devices industry.

( Industry Median: 20.91 vs. UPI: 10.60 )
UPI' s 10-Year EV-to-EBIT Range
Min: 103   Max: 355.9
Current: 10.6

103
355.9

Valuation & Return

vs
industry
vs
history
Price/Net Cash 7.80
UPI's Price/Net Cash is ranked higher than
66% of the 119 Companies
in the Global Medical Devices industry.

( Industry Median: 14.30 vs. UPI: 7.80 )
UPI' s 10-Year Price/Net Cash Range
Min: 1.81   Max: 107.2
Current: 7.8

1.81
107.2
Price/Net Current Asset Value 6.30
UPI's Price/Net Current Asset Value is ranked higher than
64% of the 174 Companies
in the Global Medical Devices industry.

( Industry Median: 9.10 vs. UPI: 6.30 )
UPI' s 10-Year Price/Net Current Asset Value Range
Min: 1.32   Max: 20.79
Current: 6.3

1.32
20.79
Price/Tangible Book 5.10
UPI's Price/Tangible Book is ranked lower than
55% of the 328 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. UPI: 5.10 )
UPI' s 10-Year Price/Tangible Book Range
Min: 0.76   Max: 12.77
Current: 5.1

0.76
12.77
Price/Median PS Value 0.90
UPI's Price/Median PS Value is ranked higher than
80% of the 338 Companies
in the Global Medical Devices industry.

( Industry Median: 1.10 vs. UPI: 0.90 )
UPI' s 10-Year Price/Median PS Value Range
Min: 0.14   Max: 4.67
Current: 0.9

0.14
4.67
Forward Rate of Return (Yacktman) -8.52
UPI's Forward Rate of Return (Yacktman) is ranked higher than
62% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 1.31 vs. UPI: -8.52 )
UPI' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0.1   Max: 37.4
Current: -8.52

0.1
37.4

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Uroplasty, Inc. was incorporated in January 1992 as a Minnesota Corporation and a wholly owned subsidiary of its original parent. In February 1995, it became a stand-alone, privately held company to a Plan of Reorganization confirmed by the U.S. Bankruptcy Court. It is a medical device Company that develops, manufactures and markets innovative, proprietary products for the treatment of voiding dysfunctions. The Company focuses on two products: Urgent PC system, which is the only FDA-approved minimally-invasive, office-based neurostimulation therapy for the treatment of urinary urgency, urinary frequency, and urge incontinence - symptoms often associated with overactive bladder (OAB); and Macroplastique, a urethral bulking agent for the treatment of adult female stress urinary incontinence mainly due to intrinsic sphincter deficiency (ISD). The physicians prefer its products because they offer an effective therapy for the patient, could be administered in office-based settings and, to the extent reimbursement are in place, provide the physicians a new profitable recurring revenue stream. The patients prefer its products because they are minimally invasive treatment alternatives and neither have the side effects associated with pharmaceutical treatment options nor the morbidity associated with surgery. The Company has a U.S. Food and Drug Administration (FDA)-qualified manufacturing facility in Minnetonka, Minnesota. It uses only medical grade solid silicone material in its tissue bulking products and do not use semi-liquid silicone gel, as was used in breast implants. Competitors offer management and curative treatments, including neurostimulation devices, tissue bulking agents and urethral sling products. The Company has registered Uroplasty, Macroplastique, VOX, PTQ and Bioplastique as trademarks with the U.S. Patent and Trademark Office and throughout the European Union. The testing, manufacturing, promotion, marketing and distribution of its products in the United States, Europe and other parts of the world are subject to regulation by numerous governmental authorities, including the FDA, the European Union and other analogous agencies.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide